SABS SAB Biotherapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1833214 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-40.9%
TTM net income YoY19.2%
TTM EPS YoY51.8%
Revenue 3-yr CAGR-72.1%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-3,244.9%
Net margin-2,579.0%
FCF margin-2,618.6%
EBITDA margin-2,895.0%
Returns
ROE-81.9%
ROA-53.2%
ROIC (approx.)-380.8%
Asset turnover0.02x
Leverage & solvency
Liabilities / assets41.2%
Debt / equity0.00x
Current ratio2.98x
Interest coverage-134.77x
Cash quality & payout
Operating cash flow / net income1.01x
Accruals ratio0.3%
Payout ratio—
Capex / revenue25.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | $114,698 |
| R&D expense | $18.08M | $16.17M | $13.40M | $10.73M | $8.97M | $7.00M | $7.66M | $7.65M |
| SG&A expense | $7.82M | $7.21M | $6.60M | $5.04M | $3.71M | $2.73M | $3.11M | $2.47M |
| Operating income | -$25.90M | -$23.38M | -$20.00M | -$15.77M | -$12.68M | -$9.73M | -$10.77M | -$10.01M |
| Interest expense | — | $62,000 | $62,745 | $63,462 | $43,292 | $64,000 | $69,565 | $70,876 |
| Net income | -$22.30M | -$22.49M | -$18.87M | -$16.86M | $45.45M | -$10.11M | -$5.20M | -$11.39M |
| EBITDA | -$25.10M | -$22.58M | -$19.27M | -$15.03M | -$11.98M | -$8.93M | -$10.02M | -$9.24M |
| EPS (basic) | -0.24 | -0.28 | -0.35 | — | 0.50 | -1.09 | -0.56 | — |
| EPS (diluted) | -0.24 | -0.28 | -0.35 | — | -0.21 | -1.09 | -0.56 | — |
| Weighted avg. shares (diluted) | 93.24M | 79.75M | 53.56M | — | 77.86M | 9.29M | 9.29M | — |
| Banking | ||||||||
| Net interest income | $1.61M | — | — | — | $612,000 | — | — | — |
| Balance sheet | ||||||||
| Cash & equivalents | $14.44M | $8.27M | $20.52M | $10.50M | $29.42M | $3.69M | $5.64M | $8.90M |
| Short-term investments | $89.61M | $94.36M | $86.87M | $86.09M | $81.46M | $2.02M | $7.21M | $11.86M |
| Current assets | $107.74M | $107.94M | $112.78M | $101.05M | $113.28M | $9.31M | $16.30M | $23.79M |
| PP&E, net | $15.65M | $14.23M | $13.81M | $13.31M | $13.11M | $13.86M | $14.61M | $15.37M |
| Total assets | $235.64M | $238.21M | $248.47M | $172.81M | $183.45M | $30.13M | $38.12M | $44.20M |
| Current liabilities | $14.80M | $11.71M | $9.85M | $10.68M | $10.79M | $10.68M | $9.65M | $7.98M |
| Total liabilities | $24.72M | $23.43M | $21.22M | $21.32M | $18.37M | $18.11M | $16.71M | $18.23M |
| Shareholders' equity | $210.92M | $214.78M | $227.25M | $151.50M | $165.07M | $12.02M | $21.41M | $25.97M |
| Shares outstanding | 91.14M | 83.49M | 75.74M | 47.61M | 47.49M | 9.29M | 9.29M | 9.29M |
| Cash flow statement | ||||||||
| Operating cash flow | -$13.02M | -$9.84M | -$14.27M | -$16.78M | -$13.05M | -$7.15M | -$7.80M | -$9.53M |
| Capital expenditure | $1.34M | $1.59M | $983,257 | — | — | — | — | $55,377 |
| Free cash flow | -$14.37M | -$11.43M | -$15.25M | — | — | — | — | -$9.59M |
| Investing cash flow | $6.07M | -$4.88M | -$65.65M | -$1.71M | -$129.87M | $5.20M | $4.67M | $9.33M |
| Financing cash flow | $13.00M | $2.36M | $89.92M | -$41,685 | $168.69M | -$173,844 | -$173,985 | $216,961 |
| Depreciation & amortization | $800,000 | $800,000 | $730,965 | $741,593 | $700,000 | $800,000 | $756,595 | $764,007 |
| Stock-based compensation | $7.44M | $7.25M | $5.46M | $3.17M | $801,000 | $627,000 | $612,951 | $674,135 |
Free plan shows the latest 8 periods; Pro shows all 23 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.